Global Lung Surfactants Market, By Indication (Respiratory Distress Syndrome (RDS), Respiratory Infections, Others), Drugs (Poractant, Beractant, Lucinactant, Calfactant, Others), Route of Administration (Intratracheal, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Lungs surfactants are administered to prevent and treat neonatal respiratory distress syndrome (RDS). RDS is a serious consequence of premature delivery that affects over 40,000 infants in the United States and Canada every year. The lungs eventually collapse due to low lung compliance caused by a functional or quantitative surfactant deficit. Surfactant, a mixture of phospholipids, neutral lipids, and proteins created by pneumocytes during pregnancy, lowers surface tension and thereby stabilizes alveoli, increasing lung compliance and reducing shortness of breath.
Data Bridge Market Research analyses that the lung surfactants market was valued at USD 173 million in 2021 and is expected to reach USD 242.28 million by 2029, registering a CAGR of 4.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Respiratory Distress Syndrome (RDS), Respiratory Infections, Others), Drugs (Poractant, Beractant, Lucinactant, Calfactant, Others), Route of Administration (Intratracheal, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
CHIESI Farmaceutici S.p.A. (Italy), ONY Biotech Inc. (U.S.), Lyomark Pharma GmbH (Germany), Windtree Therapeutics, Inc (U.S.), Aviva Systems Biology Corporation (U.S.), Boehringer Ingelheim International GmbH. (Germany), AbbVie Inc. (U.S.), Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lung surfactant is a crucial molecule in the organ. It helps to avoid pulmonary edema by lowering surface tension in alveolar cells, which helps to stabilize the alveoli. Phospholipids are present in lung surfactants, which are synthesized from animal lung extract. Natural surfactant is a substance produced by alveolar cells in the lungs that lines the alveoli and small bronchioles, preventing them from collapsing. Lung surfactant helps oxygen pass through the surface lining of the lungs and into the bloodstream.
Lung Surfactants Market Dynamics
Drivers
- High prevalence rate of respiratory infections
The rise in prevalence rate of respiratory infections will act as a major driver that will result in the expansion of the market's growth rate. Natural surfactant has been recommended to treat lung diseases, including suspected surfactant insufficiency in adults due to the promising outcomes obtained by lung surfactants in treating respiratory failure in premature babies. Aside from bronchiolitis, where surfactants were employed to stabilize narrow airways and for their putative antiviral properties, research has indicated that lung surfactants can help with pneumonia, aspiration, sepsis, and chest trauma, all of which can lead to adult respiratory distress syndrome. To clean the lungs, eliminate inhibitors, and give enough functional surfactant, surfactant bronchoalveolar lavage has been employed.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of lung surfactants market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, a surging number of government initiatives to spread awareness will expand lung surfactants market. Along with this, changing lifestyle of people and growing government favourable initiatives will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the lung surfactants market growth.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the lung surfactants market growth.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution will obstruct the growth rate of lung surfactants market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the lung surfactants market. Additionally, lack of awareness among people and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This lung surfactants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung surfactants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Lung surfactants market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Lung Surfactants Market
The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy by directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets.
On the bright side, the lung surfactants market will likely improve as respective government bodies have lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.
Global Lung Surfactants Market Scope
The lung surfactants market is segmented on the basis of indication, drug, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Others
Drugs
- Poractant
- Beractant
- Lucinactant
- Calfactant
- Others
Route of Administration
- Intratracheal
- Injectable
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Lung Surfactants Market Regional Analysis/Insights
The lung surfactants market is analysed and market size insights and trends are provided by country, indication, drug, route of administration, end-users and distribution channel as referenced above.
The countries covered in the lung surfactants market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the lung surfactants market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for specific treatment and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, high prevalence of respiratory infections and rise in adoption of newer technologies will further propel the market’s growth rate in this region.
Europe is expected to be the fastest growing region during the forecast period of 2022-2029 due to growing cases of respiratory infections in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lung Surfactants Market Share Analysis
The lung surfactants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung surfactants market.
Some of the major players operating in the lung surfactants market are:
- CHIESI Farmaceutici S.p.A. (Italy)
- ONY Biotech Inc. (U.S.)
- Lyomark Pharma GmbH (Germany)
- Windtree Therapeutics, Inc (U.S.)
- Aviva Systems Biology Corporation (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
SKU-